CN104758930B - 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 - Google Patents
一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 Download PDFInfo
- Publication number
- CN104758930B CN104758930B CN201510115729.8A CN201510115729A CN104758930B CN 104758930 B CN104758930 B CN 104758930B CN 201510115729 A CN201510115729 A CN 201510115729A CN 104758930 B CN104758930 B CN 104758930B
- Authority
- CN
- China
- Prior art keywords
- magnetic oxygenated
- graphene
- gel
- oxygenated graphene
- polyethyleneimine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 159
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 152
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 229920002873 Polyethylenimine Polymers 0.000 claims abstract description 76
- 229920001661 Chitosan Polymers 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 14
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 76
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 54
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 49
- 206010028980 Neoplasm Diseases 0.000 claims description 49
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 48
- 238000003756 stirring Methods 0.000 claims description 46
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 34
- 239000012498 ultrapure water Substances 0.000 claims description 34
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 24
- 239000013049 sediment Substances 0.000 claims description 22
- 239000012065 filter cake Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims description 11
- -1 aminopropyl Chemical group 0.000 claims description 10
- 238000013019 agitation Methods 0.000 claims description 9
- 229910002804 graphite Inorganic materials 0.000 claims description 9
- 239000010439 graphite Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 230000006196 deacetylation Effects 0.000 claims description 8
- 238000003381 deacetylation reaction Methods 0.000 claims description 8
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 8
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 8
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 238000000967 suction filtration Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000003760 magnetic stirring Methods 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 229940035857 doxorubicin hydrochloride 10 mg Drugs 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 3
- 239000000499 gel Substances 0.000 abstract description 82
- 238000012377 drug delivery Methods 0.000 abstract description 11
- 238000000015 thermotherapy Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011065 in-situ storage Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 238000006482 condensation reaction Methods 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 150000005846 sugar alcohols Polymers 0.000 abstract description 2
- KANLKAYGXGSUJC-UHFFFAOYSA-N 2,3-dihydroxypropyl dihydrogen phosphate;sodium Chemical compound [Na].OCC(O)COP(O)(O)=O KANLKAYGXGSUJC-UHFFFAOYSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 7
- 230000000118 anti-neoplastic effect Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940009456 adriamycin Drugs 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 239000004575 stone Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000013007 heat curing Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 238000005034 decoration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010062129 Tongue neoplasm Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000030940 penile carcinoma Diseases 0.000 description 2
- 201000008174 penis carcinoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013066 thyroid gland cancer Diseases 0.000 description 2
- 201000006134 tongue cancer Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510115729.8A CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510115729.8A CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104758930A CN104758930A (zh) | 2015-07-08 |
CN104758930B true CN104758930B (zh) | 2017-09-01 |
Family
ID=53641240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510115729.8A Expired - Fee Related CN104758930B (zh) | 2015-03-17 | 2015-03-17 | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104758930B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037820B (zh) * | 2015-07-14 | 2019-04-23 | 广东海洋大学 | 一种壳聚糖低温水凝胶及其制备方法 |
CN105903077B (zh) * | 2016-04-14 | 2019-05-21 | 山东景源生物科技有限公司 | 用于促进软骨再生修复的生物基质凝胶材料的制备方法、凝胶性能测定方法及应用 |
CN106074741B (zh) * | 2016-06-15 | 2017-11-24 | 腾科宝迪(厦门)生物科技有限公司 | 一种石墨烯凝胶制剂及其制备方法和应用 |
CN106362692A (zh) * | 2016-11-07 | 2017-02-01 | 深圳市北测检测技术有限公司 | 一种磁性氧化石墨烯及其应用 |
CN107583049B (zh) * | 2017-10-30 | 2021-01-01 | 江南大学 | 一种具有光热性能的可注射性水凝胶的制备方法 |
CN107961378B (zh) * | 2017-11-22 | 2020-05-05 | 江苏大学 | 一种磁性氧化石墨烯-壳聚糖/葡聚糖复合物的制备方法及应用 |
CN107970224B (zh) * | 2017-11-23 | 2020-07-31 | 江苏大学 | 一种脂质修饰磁性氧化石墨烯复合材料的制备方法及应用 |
CN108014092A (zh) * | 2017-11-23 | 2018-05-11 | 江苏大学 | 一种磁性氧化石墨烯-鱼精蛋白/羧甲基纤维素钠复合物的制备方法及应用 |
CN109078195B (zh) * | 2018-08-30 | 2021-04-02 | 青岛大学 | 壳层含石墨烯量子点、内核含磁性纳米粒子的热敏型载药微有机凝胶及其制备方法与应用 |
CN109125724A (zh) * | 2018-09-03 | 2019-01-04 | 浙江理工大学 | 一种具有磁靶向及磁热辅助光热治疗作用的药物载体的制备方法 |
CN109364300A (zh) * | 2018-12-07 | 2019-02-22 | 昂赛国际生物科技(北京)有限公司 | 一种负载间充质干细胞的温敏水凝胶液体支架及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104323985A (zh) * | 2014-11-07 | 2015-02-04 | 郑州大学 | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 |
-
2015
- 2015-03-17 CN CN201510115729.8A patent/CN104758930B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104323985A (zh) * | 2014-11-07 | 2015-02-04 | 郑州大学 | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
Enhanced Chemotherapy Effi cacy by Sequential Delivery of siRNA and Anticancer Drugs Using PEI-Grafted Graphene Oxide;Liming Zhang等;《Small》;20110118(第4期);460-464 * |
Synthesis of a novel magnetic drug delivery system composed of doxorubicin-conjugated Fe3O4 nanoparticle cores and a PEG-functionalized porous silica shell;Feng-Hua Chen等;《Chemical Communications》;20101012;8633-8635 * |
Also Published As
Publication number | Publication date |
---|---|
CN104758930A (zh) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104758930B (zh) | 一种基于磁性氧化石墨烯原位凝胶的制备方法及其应用 | |
Zhang et al. | Degradable hollow mesoporous silicon/carbon nanoparticles for photoacoustic imaging-guided highly effective chemo-thermal tumor therapy in vitro and in vivo | |
Ding et al. | A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy | |
Zhao et al. | Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application | |
CN103213967B (zh) | 一种磁性水溶性碳纳米管及其制备方法和应用 | |
CN104353075B (zh) | 一种水溶性磁性二氧化钛及其制备方法与应用 | |
CN106139144B (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金-碳纳米球及其制备方法与应用 | |
CN103099784B (zh) | 一种纳米药物颗粒、其制备方法及应用 | |
CN102898542B (zh) | 一种水溶性富勒烯及其应用 | |
CN104826127B (zh) | 光热和光动联合抗肿瘤的以叶酸介导的金纳米星为载体的药物传递系统的制备方法及应用 | |
CN104758931B (zh) | 一种基于功能化氧化石墨烯温敏水凝胶的制备方法及其应用 | |
CN106821985B (zh) | 一种适配体修饰的携氧载药多功能脂质体复合物 | |
CN103230604B (zh) | 一种磁性水溶性富勒烯及其制备方法和应用 | |
CN105906822B (zh) | 一种包覆二氧化锰片层的聚乳酸‑羟基乙酸共聚物的制备方法及应用 | |
CN106729773A (zh) | 靶向修饰的负载阿霉素的磁性纳米颗粒及制备方法及应用 | |
CN106512023A (zh) | 双功能介孔硅球复合靶向给药系统的制备方法 | |
CN104368003B (zh) | 一种透明质酸修饰的Au掺杂二氧化钛纳米管的制备方法及其应用 | |
CN104758948B (zh) | 基于金纳米星的多功能抗肿瘤靶向诊断治疗药物的制备方法及应用 | |
CN103183311A (zh) | 水溶性磁靶向性氧化石墨烯衍生物的制备方法及其应用 | |
Gao et al. | AuNRs@ MIL-101-based stimuli-responsive nanoplatform with supramolecular gates for image-guided chemo-photothermal therapy | |
CN105012271A (zh) | 一种共担载阿霉素和trail的白蛋白纳米粒靶向制剂及制备方法 | |
Ehsanimehr et al. | PEI grafted Fe3O4@ SiO2@ SBA-15 labeled FA as a pH-sensitive mesoporous magnetic and biocompatible nanocarrier for targeted delivery of doxorubicin to MCF-7 cell line | |
Du et al. | Injectable nanocomposite hydrogels for cancer therapy | |
CN104606127A (zh) | 靶向egfr的载铂类药物白蛋白纳米粒及其制备与应用 | |
CN107952070A (zh) | 双重成像引导的光热治疗多功能纳米杂化物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zhenzhong Inventor after: Zhu Xiali Inventor after: Huang Heqing Inventor after: Zhang Yingjie Inventor after: Li Zhi Inventor after: Shi Jinjin Inventor before: Zhu Xiali Inventor before: Huang Heqing Inventor before: Zhang Yingjie Inventor before: Li Zhi Inventor before: Shi Jinjin Inventor before: Zhang Zhenzhong |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Patentee after: Zhengzhou University Address before: 450001 science avenue of Zhengzhou high tech Development Zone, Zhengzhou, Henan Province, No. Patentee before: Zhengzhou University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170901 Termination date: 20180317 |